TMCnet News
Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer CollaborationWEST VALLEY CITY, Utah, March 11, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, today cut the ribbon on its new radiochemistry laboratory in West Valley City, Utah on Friday. Known as the Radiance Lab, the 5,000 square foot space will allow the company to develop and implement radioisotope separation and purification processes in advance of Nusano beginning commercial-scale radiotherapeutics ingredient production in early 2025. “Nusano is less than 12 months away from bringing critical, new radioisotope supplies to researchers, drugmakers and patients. We expect to begin producing non-carrier added lutetium-177 in Q1 2025, followed by actinium-225 in the second half of the year,” said Chris Lowe, CEO of Nusano. “Opening the Radiance Lab is a key milestone in our path to commercialization, providing collaboration and research space that will allow Nusano to offer world-class quality, processes, and scale to our customers.” Radioisotopes are the active pharmaceutical ingredients used in new and emerging cancer therapies. Existing supply chains for these treatment-enabling resources are often strained, posing a risk to patient care and ongoing drug development. Nusano is working to supply the fight against cancer by combining the company’s expertise in physics and radiochemistry to meet the medical isotope needs of today and enable the cancer radiotherapeutics of tomorrow. Anna Goldberg, director of Radiochemistry and Production Operations for Nusano, added, “Nusano’s radiochemistry team is a world-class group of experts working at the forefront of their field. The Radiance Lab is both a working laboratory where our chemists will develop methods and procedures to ensure product quality, and an innovation hub where we will explore the development of hard-to-produce and undersupplied radiosotopes. Our goal is to enable drugmakers and researchers to begin exploring cancer therapies using all the radioisotopes that are possible, versus merely those that are available.” Both Nusano’s Radiance Lab and its production facility are situated approximately 10 minutes from the Salt Lake City airport. The flagship, 190,000 square foot production facility is scheduled to open early 2025. It will include ancillary radiochemistry space, further enhancing the company’s in-house capabilities. The locations were chosen to create a supply chain that will allow the life-changing radioisotopes Nusano produces in Utah to reach drugmakers, clinics and patients across the United States – and many parts of the world – the next day. “Nusano is revolutionizing radioisotope production and creating exciting new possibilities in cancer care, and it’s happening right here in Utah,” said John Dahlstrom, executive vice president at The Wasatch Group, developer of the building housing Nusano’s Radiance Lab in the new Medical Innovation and Technology Campus in West Valley City, Utah. “We expect Nusano’s success will promote the vibrancy of this biotechnology hub – creating jobs and contributing to the continued growth of Utah’s biotech economy.” About Nusano About Wasatch Group Contacts Nusano:
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1583555-e506-454c-825d-6a29b7390395
|